
## Anthony H V Schapira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3841031/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurology, The, 2006, 5, 235-245.	10.2	2,202
2	Mitochondrial Complex I Deficiency in Parkinson's Disease. Journal of Neurochemistry, 1990, 54, 823-827.	3.9	1,860
3	Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurology, The, 2009, 8, 464-474.	10.2	1,367
4	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurology, The, 2008, 7, 583-590.	10.2	1,340
5	MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE. Lancet, The, 1989, 333, 1269.	13.7	1,248
6	Non-motor features of Parkinson disease. Nature Reviews Neuroscience, 2017, 18, 435-450.	10.2	1,182
7	Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. FEBS Letters, 1994, 345, 50-54.	2.8	1,109
8	International multicenter pilot study of the first comprehensive selfâ€completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study. Movement Disorders, 2006, 21, 916-923.	3.9	865
9	The metric properties of a novel nonâ€motor symptoms scale for Parkinson's disease: Results from an international pilot study. Movement Disorders, 2007, 22, 1901-1911.	3.9	838
10	Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Human Molecular Genetics, 2010, 19, 4861-4870.	2.9	795
11	Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurology, The, 2008, 7, 97-109.	10.2	757
12	Mitochondrial defect in Huntington's disease caudate nucleus. Annals of Neurology, 1996, 39, 385-389.	5.3	690
13	Anatomic and Disease Specificity of NADH CoQ <sub>1</sub> Reductase (Complex I) Deficiency in Parkinson's Disease. Journal of Neurochemistry, 1990, 55, 2142-2145.	3.9	670
14	Missing pieces in the Parkinson's disease puzzle. Nature Medicine, 2010, 16, 653-661.	30.7	621
15	Mitochondrial disease. Lancet, The, 2006, 368, 70-82.	13.7	561
16	Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease. Annals of Neurology, 1992, 32, S82-S87.	5.3	475
17	Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Annals of Neurology, 2012, 72, 455-463.	5.3	473
18	Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients. Movement Disorders, 2007, 22, 1623-1629.	3.9	461

#	Article	IF	CITATIONS
19	Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet, The, 1992, 339, 1375-1377.	13.7	443
20	Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains. Archives of Neurology, 2010, 67, 1464-72.	4.5	440
21	Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Annals of Neurology, 1999, 45, 25-32.	5.3	439
22	Mitochondrial diseases. Lancet, The, 2012, 379, 1825-1834.	13.7	411
23	A novel α-synuclein missense mutation in Parkinson disease. Neurology, 2013, 80, 1062-1064.	1.1	396
24	Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Movement Disorders, 2014, 29, 1476-1485.	3.9	384
25	Irreversible Inhibition of Mitochondrial Complex I by 1-Methyl-4-Phenylpyridinium: Evidence for Free Radical Involvement. Journal of Neurochemistry, 1992, 58, 786-789.	3.9	368
26	Priorities in Parkinson's disease research. Nature Reviews Drug Discovery, 2011, 10, 377-393.	46.4	364
27	The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire. Movement Disorders, 2010, 25, 704-709.	3.9	342
28	Platelet mitochondria function in Parkinson's disease. Annals of Neurology, 1992, 32, 782-788.	5.3	337
29	Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 11492-11495.	7.1	337
30	Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet, The, 2014, 384, 545-555.	13.7	336
31	Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Annals of Neurology, 1994, 35, 38-44.	5.3	333
32	BRAIN, SKELETAL MUSCLE AND PLATELET HOMOGENATE MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASE. Brain, 1992, 115, 333-342.	7.6	332
33	Genetic and environmental factors in the cause of Parkinson's disease. Annals of Neurology, 2003, 53, S16-S25.	5.3	327
34	Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. Brain, 2017, 140, 3191-3203.	7.6	323
35	Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: Effect of ageing. Journal of the Neurological Sciences, 1992, 113, 91-98.	0.6	322
36	Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. Lancet, The, 2000, 355, 299-304.	13.7	320

#	Article	IF	CITATIONS
37	Complex I Inhibitors Induce Doseâ€Đependent Apoptosis in PC12 Cells: Relevance to Parkinson's Disease. Journal of Neurochemistry, 1994, 63, 1987-1990.	3.9	318
38	Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Human Molecular Genetics, 2000, 9, 275-282.	2.9	312
39	Mitochondrial myopathies: Clinical and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA. Annals of Neurology, 1989, 26, 699-708.	5.3	309
40	Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Annals of Neurology, 1998, 44, 177-186.	5.3	301
41	Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease—Links to Parkinson's Disease. Cell Metabolism, 2013, 17, 941-953.	16.2	277
42	New insights into the cause of Parkinson's disease. Neurology, 1992, 42, 2241-2241.	1.1	275
43	Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochimica Et Biophysica Acta - Bioenergetics, 1999, 1410, 159-170.	1.0	271
44	Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. Annals of Neurology, 1992, 32, S94-S100.	5.3	263
45	Novel pharmacological targets for the treatment of Parkinson's disease. Nature Reviews Drug Discovery, 2006, 5, 845-854.	46.4	262
46	Neuroprotection in Parkinson Disease. JAMA - Journal of the American Medical Association, 2004, 291, 358.	7.4	258
47	Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain, 2014, 137, 1481-1495.	7.6	258
48	Mitochondria and degenerative disorders. American Journal of Medical Genetics Part A, 2001, 106, 27-36.	2.4	244
49	Complex I, Iron, and ferritin in Parkinson's disease substantia nigra. Annals of Neurology, 1994, 36, 876-881.	5.3	229
50	Rotigotine transdermal patch in early Parkinson's disease: A randomized, doubleâ€blind, controlled study versus placebo and ropinirole. Movement Disorders, 2007, 22, 2398-2404.	3.9	214
51	Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations. JAMA Neurology, 2020, 77, 427.	9.0	213
52	Antioxidant Treatment of Patients With Friedreich Ataxia. Archives of Neurology, 2005, 62, 621.	4.5	211
53	Mitochondria in the etiology and pathogenesis of parkinson's disease. Annals of Neurology, 1998, 44, S89-98.	5.3	206
54	Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal. Movement Disorders, 1994, 9, 125-138.	3.9	199

#	Article	IF	CITATIONS
55	Neurobiology and treatment of Parkinson's disease. Trends in Pharmacological Sciences, 2009, 30, 41-47.	8.7	193
56	Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends in Neurosciences, 2000, 23, S117-S126.	8.6	185
57	Glucocerebrosidase and Parkinson disease: Recent advances. Molecular and Cellular Neurosciences, 2015, 66, 37-42.	2.2	184
58	Mitochondrial and lysosomal biogenesis are activated following <scp>PINK</scp> 1/parkinâ€mediated mitophagy. Journal of Neurochemistry, 2016, 136, 388-402.	3.9	184
59	Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects. Lancet, The, 2000, 355, 389-394.	13.7	183
60	Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Human Molecular Genetics, 2000, 9, 2683-2689.	2.9	182
61	Evolution of Prodromal Clinical Markers of Parkinson Disease in a <i>GBA</i> Mutation–Positive Cohort. JAMA Neurology, 2015, 72, 201.	9.0	180
62	Etiology of Parkinson's disease. Neurology, 2006, 66, S10-23.	1.1	179
63	Mitochondrial dysfunction in neurodegenerative disorders. Biochimica Et Biophysica Acta - Bioenergetics, 1998, 1366, 225-233.	1.0	178
64	Timing of treatment initiation in Parkinson's disease: A need for reappraisal?. Annals of Neurology, 2006, 59, 559-562.	5.3	178
65	Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurology, The, 2013, 12, 747-755.	10.2	175
66	Silencing of PINK1 Expression Affects Mitochondrial DNA and Oxidative Phosphorylation in DOPAMINERGIC Cells. PLoS ONE, 2009, 4, e4756.	2.5	173
67	Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Human Molecular Genetics, 2016, 25, 3432-3445.	2.9	171
68	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations. JAMA Neurology, 2017, 74, 216.	9.0	171
69	Leber's Hereditary Optic Neuropathy (LHON) Pathogenic Mutations Induce Mitochondrial-dependent Apoptotic Death in Transmitochondrial Cells Incubated with Galactose Medium. Journal of Biological Chemistry, 2003, 278, 4145-4150.	3.4	169
70	Full length article. Brain Research, 1997, 777, 110-118.	2.2	167
71	TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurology, The, 2006, 5, 1013-1020.	10.2	167
72	The relationship between glucocerebrosidase mutations and Parkinson disease. Journal of Neurochemistry, 2016, 139, 77-90.	3.9	167

#	Article	IF	CITATIONS
73	Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nature Reviews Neurology, 2010, 6, 309-317.	10.1	166
74	Waking up to sleep episodes in Parkinson's Disease. Movement Disorders, 2000, 15, 212-215.	3.9	163
75	<i>PRRT2</i> gene mutations. Neurology, 2012, 79, 2115-2121.	1.1	159
76	Science, medicine, and the future: Parkinson's disease. BMJ: British Medical Journal, 1999, 318, 311-314.	2.3	151
77	Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. Journal of the Neurological Sciences, 1998, 158, 24-29.	0.6	147
78	G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Human Molecular Genetics, 2012, 21, 4201-4213.	2.9	147
79	Sleep attacks (sleep episodes) with pergolide. Lancet, The, 2000, 355, 1332-1333.	13.7	146
80	Human complex I defects in neurodegenerative diseases. Biochimica Et Biophysica Acta - Bioenergetics, 1998, 1364, 261-270.	1.0	145
81	PINK1 disables the anti-fission machinery to segregate damaged mitochondria for mitophagy. Journal of Cell Biology, 2016, 213, 163-171.	5.2	145
82	Severe Impairment of Complex I–Driven Adenosine Triphosphate Synthesis in Leber Hereditary Optic Neuropathy Cybrids. Archives of Neurology, 2005, 62, 730.	4.5	144
83	Ambroxol effects in glucocerebrosidase and αâ€synuclein transgenic mice. Annals of Neurology, 2016, 80, 766-775.	5.3	143
84	Mutant Parkin Impairs Mitochondrial Function and Morphology in Human Fibroblasts. PLoS ONE, 2010, 5, e12962.	2.5	140
85	Cytochrome c Oxidase Deficiency Associated with the First Stop-Codon Point Mutation in Human mtDNA. American Journal of Human Genetics, 1998, 63, 29-36.	6.2	135
86	Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Scientific Reports, 2016, 6, 31380.	3.3	133
87	Oxidative Stress and Parkinson's Diseasea. Annals of the New York Academy of Sciences, 1996, 786, 217-223.	3.8	132
88	A Missense Mutation of Cytochrome Oxidase Subunit II Causes Defective Assembly and Myopathy. American Journal of Human Genetics, 1999, 65, 1030-1039.	6.2	131
89	Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Annals of Neurology, 2000, 47, 80-86.	5.3	131
90	Oxidative-phosphorylation defects in liver of patients with Wilson's disease. Lancet, The, 2000, 356, 469-474.	13.7	130

#	Article	IF	CITATIONS
91	Why have we failed to achieve neuroprotection in Parkinson's disease?. Annals of Neurology, 2008, 64, S101-S110.	5.3	125
92	Mitochondrial function and parental sex effect in Huntington's disease. Lancet, The, 1990, 336, 749.	13.7	123
93	Cells Bearing Mutations Causing Leber's Hereditary Optic Neuropathy Are Sensitized to Fas-induced Apoptosis. Journal of Biological Chemistry, 2002, 277, 5810-5815.	3.4	122
94	Therapeutic prospects for Parkinson disease. Annals of Neurology, 2013, 74, 337-347.	5.3	122
95	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Human Molecular Genetics, 2013, 22, 1039-1049.	2.9	122
96	Molecular Mechanisms in Mitochondrial DNA Depletion Syndrome. Human Molecular Genetics, 1997, 6, 935-942.	2.9	121
97	No evidence for substrate accumulation in Parkinson brains with <i>GBA</i> mutations. Movement Disorders, 2015, 30, 1085-1089.	3.9	121
98	α-Synuclein and Mitochondrial Dysfunction in Parkinson's Disease. Molecular Neurobiology, 2013, 47, 587-597.	4.0	120
99	Treatment Options in the Modern Management of Parkinson Disease. Archives of Neurology, 2007, 64, 1083.	4.5	116
100	Mitochondrial DNA analysis in Parkinson's disease. Movement Disorders, 1990, 5, 294-297.	3.9	112
101	Oxidative stress and mitochondrial dysfunction in neurodegeneration. Current Opinion in Neurology, 1996, 9, 260-264.	3.6	112
102	Monoamine Oxidase B Inhibitors for the Treatment of Parkinson's Disease. CNS Drugs, 2011, 25, 1061-1071.	5.9	111
103	Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Movement Disorders, 2012, 27, 526-532.	3.9	108
104	Glucocerebrosidase 1 deficient <i>Danio rerio</i> mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death. Human Molecular Genetics, 2015, 24, 6640-6652.	2.9	108
105	Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Annals of Medicine, 2013, 45, 511-521.	3.8	107
106	Liver failure associated with mitochondrial DNA depletion. Journal of Hepatology, 1998, 28, 556-563.	3.7	106
107	Leber hereditary optic neuropathy mtDNA mutations disrupt glutamate transport in cybrid cell lines. Brain, 2004, 127, 2183-2192.	7.6	106
108	A randomized, doubleâ€blind, placeboâ€controlled trial of safinamide as addâ€on therapy in early Parkinson's disease patients. Movement Disorders, 2012, 27, 106-112.	3.9	106

#	Article	IF	CITATIONS
109	Etiology and Pathogenesis of Parkinson Disease. Neurologic Clinics, 2009, 27, 583-603.	1.8	105
110	Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins. Brain Research, 1998, 809, 12-17.	2.2	102
111	A clinical and family history study of Parkinson's disease in heterozygous <i>glucocerebrosidase</i> mutation carriers. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 853-854.	1.9	99
112	The role of glucocerebrosidase in Parkinson disease pathogenesis. FEBS Journal, 2018, 285, 3591-3603.	4.7	99
113	Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. Journal of Neurochemistry, 2004, 91, 1075-1081.	3.9	98
114	Extended-release pramipexole in advanced Parkinson disease. Neurology, 2011, 77, 767-774.	1.1	97
115	Mitochondrial function in Parkinson's disease. Annals of Neurology, 1992, 32, S116-S124.	5.3	96
116	Mitochondrial dysfunction associated with neuronal death following status epilepticus in rat. Epilepsy Research, 2002, 48, 157-168.	1.6	96
117	Mitochondrial Contribution to Parkinson's Disease Pathogenesis. Parkinson's Disease, 2011, 2011, 1-7.	1.1	95
118	A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need. PLoS ONE, 2013, 8, e57221.	2.5	95
119	Nuclear complementation restores mtDNA levels in cultured cells from a patient with mtDNA depletion. American Journal of Human Genetics, 1993, 53, 663-9.	6.2	95
120	Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: An in vivo 31P magnetic resonance spectroscopy study. Cardiovascular Research, 2001, 52, 111-119.	3.8	93
121	In vivo skeletal muscle mitochondrial function in Leber's hereditary optic neuropathy assessed by31P magnetic resonance spectroscopy. Annals of Neurology, 1997, 42, 573-579.	5.3	91
122	Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Molecular Neurodegeneration, 2015, 10, 41.	10.8	90
123	Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. Brain, 2019, 142, 3592-3604.	7.6	90
124	Recent developments in biomarkers in Parkinson disease. Current Opinion in Neurology, 2013, 26, 395-400.	3.6	88
125	Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. Journal of Neurochemistry, 2009, 110, 1005-1013.	3.9	87
126	Randomized, doubleâ€blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Movement Disorders, 2010, 25, 2542-2549.	3.9	87

#	Article	IF	CITATIONS
127	Oxidative stress in Parkinson's disease. Neuropathology and Applied Neurobiology, 1995, 21, 3-9.	3.2	86
128	Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Annals of Neurology, 2006, 60, 253-255.	5.3	86
129	Genetic and clinical heterogeneity in paroxysmal kinesigenic dyskinesia: Evidence for a third EKD gene. Movement Disorders, 2002, 17, 717-725.	3.9	85
130	Mitochondrial dysfunction in glaucoma: Understanding genetic influences. Mitochondrion, 2012, 12, 202-212.	3.4	85
131	Restless Legs Syndrome. Drugs, 2004, 64, 149-158.	10.9	84
132	Central role and mechanisms of βâ€cell dysfunction and death in friedreich ataxia–associated diabetes. Annals of Neurology, 2012, 72, 971-982.	5.3	84
133	Pathogenic Mechanisms of Neurodegeneration in Parkinson Disease. Neurologic Clinics, 2015, 33, 1-17.	1.8	84
134	Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Synapse, 2017, 71, e21967.	1.2	84
135	Clinical correlates of mitochondrial function in Huntington's disease muscle. Movement Disorders, 2007, 22, 1715-1721.	3.9	83
136	Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications. Neuroscientist, 2018, 24, 540-559.	3.5	81
137	Quantitation of a mitochondrial DNA deletion in Parkinson's disease. FEBS Letters, 1992, 299, 218-222.	2.8	79
138	Mitochondrial dysfunction associated with glucocerebrosidase deficiency. Neurobiology of Disease, 2016, 90, 43-50.	4.4	79
139	Complex I function in familial and sporadic dystonia. Annals of Neurology, 1997, 41, 556-559.	5.3	78
140	End-of-dose Wearing Off in Parkinson Disease. Clinical Neuropharmacology, 2006, 29, 312-321.	0.7	78
141	Visual short-term memory deficits associated with GBA mutation and Parkinson's disease. Brain, 2014, 137, 2303-2311.	7.6	77
142	Platelet mitochondrial function in Leber's hereditary optic neuropathy. Journal of the Neurological Sciences, 1994, 122, 80-83.	0.6	76
143	PINK1-parkin-dependent mitophagy involves ubiquitination of mitofusins 1 and 2: Implications for Parkinson disease pathogenesis. Autophagy, 2011, 7, 243-245.	9.1	75
144	Neuroprotection and dopamine agonists. Neurology, 2002, 58, S9-18.	1.1	75

#	Article	IF	CITATIONS
145	Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease. Brain Research, 1993, 627, 349-353.	2.2	74
146	Smoking and mitochondrial function: a model for environmental toxins. QJM - Monthly Journal of the Association of Physicians, 1993, 86, 657-660.	0.5	74
147	Mitochondrial DNA (mtDNA) diseases: correlation of genotype to phenotype. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1995, 1271, 135-140.	3.8	74
148	The influence of nuclear background on the biochemical expression of 3460 Leber's hereditary optic neuropathy. Annals of Neurology, 1998, 44, 187-193.	5.3	74
149	Molecular changes in the postmortem parkinsonian brain. Journal of Neurochemistry, 2016, 139, 27-58.	3.9	74
150	Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons. Scientific Reports, 2018, 8, 1385.	3.3	74
151	Recharging mitochondrial batteries in old eyes. Near infra-red increases ATP. Experimental Eye Research, 2014, 122, 50-53.	2.6	73
152	Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. Movement Disorders, 2019, 34, 9-21.	3.9	73
153	Molecular defects of NADH-ubiquinone oxidoreductase (Complex I) in mitochondrial diseases. Journal of Bioenergetics and Biomembranes, 1988, 20, 365-382.	2.3	72
154	A new family with paroxysmal exercise induced dystonia and migraine: a clinical and genetic study. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 609-614.	1.9	72
155	Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon. Annals of Neurology, 1993, 33, 407-411.	5.3	71
156	Friedreich's Ataxia: From Disease Mechanisms to Therapeutic Interventions. Antioxidants and Redox Signaling, 2006, 8, 438-443.	5.4	71
157	Mitochondrial Pathology in Parkinson's Disease. Mount Sinai Journal of Medicine, 2011, 78, 872-881.	1.9	69
158	PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Movement Disorders, 2011, 26, 1259-1265.	3.9	69
159	International cooperative ataxia rating scale (ICARS): Appropriate for studies of Friedreich's ataxia?. Movement Disorders, 2005, 20, 1585-1591.	3.9	68
160	The genetics of Parkinson's disease. British Medical Bulletin, 2015, 114, 39-52.	6.9	68
161	The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1. American Journal of Neuroradiology, 2015, 36, 229-235.	2.4	68
162	Timing of deep brain stimulation in Parkinson disease: A need for reappraisal?. Annals of Neurology, 2013, 73, 565-575.	5.3	67

#	Article	IF	CITATIONS
163	MOLECULAR BASIS OF MITOCHONDRIAL MYOPATHIES: POLYPEPTIDE ANALYSIS IN COMPLEX-1 DEFICIENCY. Lancet, The, 1988, 331, 500-503.	13.7	66
164	Mitochondrial respiratory chain function in multiple system atrophy. Movement Disorders, 1997, 12, 418-422.	3.9	65
165	Neuroprotection for Parkinson's disease: Prospects and promises. Annals of Neurology, 2003, 53, S1-S2.	5.3	65
166	Disease modification in Parkinson's disease. Lancet Neurology, The, 2004, 3, 362-368.	10.2	65
167	Mitochondrial Dysfunction in Neurodegenerative Diseases. Neurochemical Research, 2008, 33, 2502-2509.	3.3	65
168	The H50Q Mutation Induces a 10-fold Decrease in the Solubility of α-Synuclein. Journal of Biological Chemistry, 2015, 290, 2395-2404.	3.4	65
169	Evaluation of the detection of <i>GBA</i> missense mutations and other variants using the Oxford Nanopore MinION. Molecular Genetics & amp; Genomic Medicine, 2019, 7, e564.	1.2	65
170	A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease. Journal of the Neurological Sciences, 1994, 125, 77-81.	0.6	64
171	Functional consequences of the 3460-bp mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Journal of the Neurological Sciences, 1999, 165, 10-17.	0.6	64
172	Perspectives on recent advances in the understanding and treatment of Parkinson's disease. European Journal of Neurology, 2009, 16, 1090-1099.	3.3	64
173	Somatic copy number gains of α-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains. Brain, 2018, 141, 2419-2431.	7.6	63
174	GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells, 2022, 11, 1261.	4.1	61
175	Mitochondrial Myopathy with a Defect of Mitochondrial-Protein Transport. New England Journal of Medicine, 1990, 323, 37-42.	27.0	59
176	Mitochondrial dysfunction in neurodegeneration. Journal of Bioenergetics and Biomembranes, 1997, 29, 175-183.	2.3	59
177	Detection of Nitrosyl Complexes in Human Substantia Nigra, in Relation to Parkinson's Disease. Biochemical and Biophysical Research Communications, 1996, 228, 298-305.	2.1	58
178	Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology, 2009, 72, S44-50.	1.1	58
179	Clinical prodromes of neurodegeneration in Anderson-Fabry disease. Neurology, 2015, 84, 1454-1464.	1.1	58
180	Clinical, biochemical and molecular genetic features of Leber's hereditary optic neuropathy. Biochimica Et Biophysica Acta - Bioenergetics, 1999, 1410, 147-158.	1.0	57

#	Article	IF	CITATIONS
181	A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers. Stem Cell Reports, 2017, 8, 728-742.	4.8	57
182	Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. Neuropharmacology, 2004, 46, 562-569.	4.1	56
183	Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Annals of Neurology, 2001, 49, 590-6.	5.3	56
184	Dopaminergic Neuronal Imaging in Genetic Parkinson's Disease: Insights into Pathogenesis. PLoS ONE, 2013, 8, e69190.	2.5	55
185	Insights into the structural biology of Gaucher disease. Experimental Neurology, 2017, 298, 180-190.	4.1	55
186	Mitochondrial function in neurodegeneration and ageing. Mutation Research - DNAging, 1992, 275, 133-143.	3.2	54
187	Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies. Journal of Neural Transmission Supplementum, 1997, 51, 167-173.	0.5	54
188	Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3214-3215.	7.1	54
189	Analysis of mutant DNA polymerase Î <sup>3</sup> in patients with mitochondrial DNA depletion. Human Mutation, 2009, 30, 248-254.	2.5	52
190	The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice. Brain, 2017, 140, 2706-2721.	7.6	52
191	Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Annals of Neurology, 2003, 53, S149-S159.	5.3	51
192	Calcium dysregulation in Parkinson's disease. Brain, 2013, 136, 2015-2016.	7.6	50
193	Mitochondrial DNA mutation underlying Leigh's syndrome: Clinical, pathological, biochemical, and genetic studies of a patient presenting with progressive myoclonic epilepsy. Journal of the Neurological Sciences, 1994, 121, 57-65.	0.6	49
194	The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. Movement Disorders, 2008, 23, S515-S520.	3.9	49
195	Mitochondrial impairment increases FL-PINK1 levels by calcium-dependent gene expression. Neurobiology of Disease, 2014, 62, 426-440.	4.4	49
196	The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 2. American Journal of Neuroradiology, 2015, 36, 236-244.	2.4	49
197	Brain Microglial Activation Increased in Glucocerebrosidase ( <scp><i>GBA</i></scp> ) Mutation Carriers without Parkinson's disease. Movement Disorders, 2021, 36, 774-779.	3.9	49
198	Mitochondrial DNA Depletion Syndrome is Expressed in Amniotic Fluid Cell Cultures. American Journal of Pathology, 1999, 155, 67-70.	3.8	48

#	Article	IF	CITATIONS
199	Targeting Mitochondria for Neuroprotection in Parkinson's Disease. Antioxidants and Redox Signaling, 2012, 16, 965-973.	5.4	45
200	Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A). Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 248-250.	1.9	44
201	Isolation of transcriptomal changes attributable to LHON mutations and the cybridization process. Brain, 2005, 128, 1026-1037.	7.6	44
202	Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research. PLoS ONE, 2012, 7, e43099.	2.5	44
203	Evolution of prodromal parkinsonian features in a cohort of <i>GBA</i> mutation-positive individuals: a 6-year longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1091-1097.	1.9	44
204	Mitochondrial complex I deficiency in Parkinson's disease. Advances in Neurology, 1993, 60, 288-91.	0.8	44
205	Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion body myositis assessed by 31P-magnetic resonance spectroscopy. Brain, 1998, 121, 2119-2126.	7.6	43
206	Anaesthetics increase light emission from aequorin at constant ionised calcium. Nature, 1980, 284, 168-169.	27.8	42
207	Cytochrome oxidase immunohistochemistry: clues for genetic mechanisms. Brain, 2000, 123, 591-600.	7.6	42
208	Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models. Scientific Reports, 2016, 6, 25344.	3.3	42
209	Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation. Neurobiology of Disease, 2020, 134, 104620.	4.4	42
210	Safinamide in the treatment of Parkinson's disease. Expert Opinion on Pharmacotherapy, 2010, 11, 2261-2268.	1.8	41
211	Resistance to the most common optic neuropathy is associated with systemic mitochondrial efficiency. Neurobiology of Disease, 2015, 82, 78-85.	4.4	41
212	L-Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain. Movement Disorders, 1995, 10, 295-297.	3.9	40
213	Practical recommendations for the process of proposing, planning and writing a neurological management guideline by <scp>EAN</scp> task forces. European Journal of Neurology, 2015, 22, 1505-1510.	3.3	40
214	Free radicals and mitochondrial dysfunction in Parkinson's disease. Biochemical Society Transactions, 1993, 21, 367-370.	3.4	39
215	Analysis of the trinucleotide CAG repeat from the DNA polymerase Î <sup>3</sup> gene (POLG) in patients with Parkinson's disease. Neuroscience Letters, 2005, 376, 56-59.	2.1	39
216	The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance. Annals of Medicine, 2021, 53, 611-625.	3.8	39

#	Article	IF	CITATIONS
217	Rationale for delayedâ€start study of pramipexole in Parkinson's disease: The PROUD study. Movement Disorders, 2010, 25, 1627-1632.	3.9	38
218	Hunting for genes in essential tremor. European Journal of Neurology, 2008, 15, 889-890.	3.3	37
219	Mitochondrial myopathies and encephalomyopathies. European Journal of Clinical Investigation, 1999, 29, 886-898.	3.4	36
220	The Importance of LRRK2 Mutations in Parkinson Disease. Archives of Neurology, 2006, 63, 1225.	4.5	36
221	Analysis of the factors influencing the cardiac phenotype in Friedreich's ataxia. Movement Disorders, 2010, 25, 846-852.	3.9	36
222	Efficacy, safety, and tolerability of overnight switching from immediate―to once daily extendedâ€release pramipexole in early Parkinson's disease. Movement Disorders, 2010, 25, 2326-2332.	3.9	36
223	Excessive daytime sleepiness in Parkinson's disease. Neurology, 2004, 63, S24-7.	1.1	36
224	Dopamine agonists in Parkinson's disease. Expert Review of Neurotherapeutics, 2008, 8, 671-677.	2.8	35
225	Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing. Acta Neuropathologica Communications, 2019, 7, 219.	5.2	35
226	Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons. Human Molecular Genetics, 2020, 29, 1716-1728.	2.9	35
227	Secondary abnormalities of mitochondrial DNA associated with neurodegeneration. Biochemical Society Symposia, 1999, 66, 99-110.	2.7	34
228	Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. Journal of Parkinson's Disease, 2022, 12, 557-570.	2.8	34
229	Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments. Neurobiology of Disease, 2022, 166, 105663.	4.4	34
230	Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication. Biochemical Journal, 1995, 305, 817-822.	3.7	33
231	Evolution and clustering of prodromal parkinsonian features in <i>GBA1</i> carriers. Movement Disorders, 2019, 34, 1365-1373.	3.9	33
232	Human mitochondrial complex I dysfunction. Biochimica Et Biophysica Acta - Bioenergetics, 1992, 1101, 198-203.	1.0	33
233	Mitochondrial Dysfunction in Neurodegenerative Disorders and Ageing. Advances in Experimental Medicine and Biology, 2001, 487, 229-251.	1.6	32
234	A clinical and genetic study of SPG5A linked autosomal recessive hereditary spastic paraplegia. Neurology, 2003, 61, 235-238.	1.1	32

#	Article	IF	CITATIONS
235	Diagnosing restless legs syndrome (RLS) in primary care. Current Medical Research and Opinion, 2004, 20, 1785-1795.	1.9	32
236	Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment. Movement Disorders, 2016, 31, 830-835.	3.9	32
237	Pathogenesis of Parkinson's disease. Baillière's Clinical Neurology, 1997, 6, 15-36.	0.2	32
238	Mitochondrial function in Alzheimer's disease. Lancet, The, 1993, 341, 969-970.	13.7	31
239	Proximal myotonic myopathy (PROMM) presenting as myotonia during pregnancy. Neuromuscular Disorders, 1999, 9, 144-149.	0.6	31
240	α-Synuclein structural features inhibit harmful polyunsaturated fatty acid oxidation, suggesting roles in neuroprotection. Journal of Biological Chemistry, 2017, 292, 6927-6937.	3.4	31
241	Chaperone-mediated autophagy as a therapeutic target for Parkinson disease. Expert Opinion on Therapeutic Targets, 2018, 22, 823-832.	3.4	31
242	A cue to queue for CoQ?. Neurology, 2001, 57, 375-376.	1.1	30
243	Early versus delayed initiation of entacapone in levodopaâ€ŧreated patients with Parkinson's disease: a longâ€ŧerm, retrospective analysis. European Journal of Neurology, 2009, 16, 1305-1311.	3.3	30
244	Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa–Undertreated Parkinson Disease. Clinical Neuropharmacology, 2012, 35, 174-181.	0.7	30
245	Sphingolipid changes in Parkinson L444P <i>GBA</i> mutation fibroblasts promote α-synuclein aggregation. Brain, 2022, 145, 1038-1051.	7.6	30
246	Mitochondrial function in Huntington's disease: Clues for pathogenesis and prospects for treatment. Annals of Neurology, 1997, 41, 141-142.	5.3	29
247	Drug selection and timing of initiation of treatment in early Parkinson's disease. Annals of Neurology, 2008, 64, S47-S55.	5.3	29
248	Characterization of a novel TYMP splice site mutation associated with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Neuromuscular Disorders, 2009, 19, 151-154.	0.6	29
249	The 14484 ND6 mtDNA mutation in Leber hereditary optic neuropathy does not affect fibroblast complex I activity. American Journal of Human Genetics, 1995, 57, 1501-2.	6.2	29
250	Antibodies to human optic nerve in Leber's hereditary optic neuropathy. Journal of the Neurological Sciences, 1995, 130, 134-138.	0.6	28
251	The role of the alpha -synuclein gene mutation in patients with sporadic Parkinson's disease in the United Kingdom. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 378-379.	1.9	28
252	Future directions in the treatment of Parkinson's disease. Movement Disorders, 2007, 22, S385-S391.	3.9	28

#	Article	IF	CITATIONS
253	Retinal thinning in Gaucher disease patients and carriers: Results of a pilot study. Molecular Genetics and Metabolism, 2013, 109, 221-223.	1.1	28
254	Exploring the Genotype–Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers. Frontiers in Neurology, 2021, 12, 694764.	2.4	28
255	The molecular pathology of respiratory-chain dysfunction in human mitochondrial myopathies. Biochimica Et Biophysica Acta - Bioenergetics, 1990, 1018, 217-222.	1.0	27
256	Sensitivity of respiratory chain activities to lipid peroxidation: effect of vitamin E deficiency. Biochemical Journal, 2001, 357, 887-892.	3.7	27
257	Uniting Chinese across Asia: the LRRK2 Gly2385Arg risk variant. European Journal of Neurology, 2008, 15, 203-204.	3.3	27
258	Aetiopathogenesis of Parkinson's disease. Journal of Neurology, 2011, 258, 307-310.	3.6	27
259	Nuclear and mitochondrial genetics in Parkinson's disease Journal of Medical Genetics, 1995, 32, 411-414.	3.2	26
260	A MITOCHONDRIAL ENCEPHALOMYOPATHY WITH SPECIFIC DEFICIENCIES OF TWO RESPIRATORY CHAIN POLYPEPTIDES AND A CIRCULATING AUTOANTIBODY TO A MITOCHONDRIAL MATRIX PROTEIN. Brain, 1990, 113, 419-432.	7.6	25
261	Mitochondrial DNA Mutations and Mitochondrial Dysfunction in Epilepsy. Epilepsia, 1999, 40, 33-40.	5.1	25
262	Updated guidelines for the management of Parkinson's disease. British Journal of Hospital Medicine, 2001, 62, 456-470.	0.2	25
263	A case of mitochondrial myopathy, lactic acidosis and complex I deficiency. Journal of Neurology, 1990, 237, 399-404.	3.6	24
264	Rasagiline. Nature Reviews Drug Discovery, 2005, 4, 625-626.	46.4	24
265	Coordinating outcomes measurement in ataxia research: Do some widely used generic rating scales tick the boxes?. Movement Disorders, 2006, 21, 1396-1403.	3.9	24
266	Friedreich's ataxia impact scale: A new measure striving to provide the flexibility required by today's studies. Movement Disorders, 2009, 24, 984-992.	3.9	24
267	Nonmotor Symptoms in Experimental Models of Parkinson's Disease. International Review of Neurobiology, 2017, 133, 63-89.	2.0	24
268	Neuroprotection in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, S41-S43.	2.2	23
269	Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. Npj Parkinson's Disease, 2021, 7, 48.	5.3	23
270	A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. Journal of Neurology, 2022, 269, 1335-1352.	3.6	23

#	Article	IF	CITATIONS
271	Consensus on the treatment of dysphagia in Parkinson's disease. Journal of the Neurological Sciences, 2021, 430, 120008.	0.6	23
272	Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function. Journal of Anatomy, 1993, 183 ( Pt 3), 451-61.	1.5	23
273	Mitochondrial myopathies: genetic defects. Biochemical Society Transactions, 1990, 18, 519-522.	3.4	22
274	Assessment of <i>In Vitro</i> and <i>In Vivo</i> Mitochondrial Function in Friedreich's Ataxia and Huntington's Disease. , 2004, 277, 293-308.		22
275	Patientâ€reported convenience of onceâ€daily versus threeâ€timesâ€daily dosing during longâ€term studies of pramipexole in early and advanced Parkinson's disease. European Journal of Neurology, 2013, 20, 50-56.	3.3	22
276	Mitochondrial disorders. Current Opinion in Neurology, 2000, 13, 527-532.	3.6	20
277	Nitric oxide enhances MPP+inhibition of complex I. FEBS Letters, 2001, 504, 50-52.	2.8	20
278	L444P Gba1 mutation increases formation and spread of α-synuclein deposits in mice injected with mouse α-synuclein pre-formed fibrils. PLoS ONE, 2020, 15, e0238075.	2.5	20
279	Causes of neuronal death in Parkinson's disease. Advances in Neurology, 2001, 86, 155-62.	0.8	20
280	Mitochondrial disorders: an overview. Journal of Bioenergetics and Biomembranes, 1997, 29, 105-107.	2.3	19
281	Inborn and Induced Defects of Mitochondria. Archives of Neurology, 1998, 55, 1293.	4.5	19
282	Mitochondrial Dysfunction in Friedreich's Ataxia. NeuroSignals, 2001, 10, 263-270.	0.9	19
283	DJ-1 is a redox sensitive adapter protein for high molecular weight complexes involved in regulation of catecholamine homeostasis. Human Molecular Genetics, 2017, 26, 4028-4041.	2.9	19
284	Ablation of the pro-inflammatory master regulator miR-155 does not mitigate neuroinflammation or neurodegeneration in a vertebrate model of Gaucher's disease. Neurobiology of Disease, 2019, 127, 563-569.	4.4	19
285	Mitochondrial disorders. Current Opinion in Genetics and Development, 1993, 3, 457-465.	3.3	18
286	Neuromyelitis optica (Devic's syndrome): no association with the primary mitochondrial DNA mutations found in Leber hereditary optic neuropathy Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 85-87.	1.9	18
287	Two pregnant women with vomiting and fits. American Journal of Obstetrics and Gynecology, 1997, 177, 1539-1540.	1.3	18
288	MitBASE : a comprehensive and integrated mitochondrial DNA database. The present status. Nucleic Acids Research, 2000, 28, 148-152.	14.5	18

#	Article	IF	CITATIONS
289	Etiopathogenesis and treatment of Parkinson's disease. Current Topics in Medicinal Chemistry, 2009, 9, 860-8.	2.1	18
290	Two-dimensional protein mapping by gold stain and immunoblotting. Analytical Biochemistry, 1988, 169, 167-171.	2.4	17
291	Mitochondrial DNA in focal dystonia: A cybrid analysis. Annals of Neurology, 1998, 44, 258-261.	5.3	17
292	MitBASE: a comprehensive and integrated mitochondrial DNA database. Nucleic Acids Research, 1999, 27, 128-133.	14.5	17
293	Immunological Phenotyping of Fibroblast Cultures from Patients with a Mitochondrial Respiratory Chain Deficit. Laboratory Investigation, 2001, 81, 1069-1077.	3.7	17
294	Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors. Journal of the Neurological Sciences, 2009, 278, 44-53.	0.6	17
295	The measurement and importance of nonâ€motor symptoms in Parkinson disease. European Journal of Neurology, 2015, 22, 2-3.	3.3	17
296	Sensitivity of respiratory chain activities to lipid peroxidation: effect of vitamin E deficiency. Biochemical Journal, 2001, 357, 887.	3.7	16
297	Transient Horner's syndrome during lumbar epidural anaesthesia. European Journal of Neurology, 2008, 15, 530-531.	3.3	16
298	Parkinson disease clinical subtypes and their implications. Nature Reviews Neurology, 2011, 7, 247-248.	10.1	16
299	Targeting Mitochondria for Neuroprotection in Parkinson Disease. JAMA Neurology, 2014, 71, 537.	9.0	16
300	Metabolic enzyme expression in dopaminergic neurons in Parkinson's disease: An in situ hybridization study. Annals of Neurology, 2001, 50, 142-149.	5.3	15
301	Summary of GIGYF2 studies in Parkinson's disease: the burden of proof. European Journal of Neurology, 2010, 17, 175-176.	3.3	15
302	The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. Neurology, 2000, 55, S65-8; discussion S69-71.	1.1	15
303	Biochemical and molecular aspects of human mitochondrial respiratory chain disorders. Biochemical Society Transactions, 1990, 18, 517-519.	3.4	14
304	Pramipexole Reduces Phosphorylation of α-Synuclein at Serine-129. Journal of Molecular Neuroscience, 2013, 51, 573-580.	2.3	14
305	Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease. CNS Drugs, 2020, 34, 915-923.	5.9	14
306	Mitochondrial myopathies: clinical defects. Biochemical Society Transactions, 1990, 18, 523-526.	3.4	13

#	Article	IF	CITATIONS
307	Early Versus Delayed Initiation of Pharmacotherapy in Parkinson's Disease. Drugs, 2014, 74, 645-657.	10.9	13
308	Mitochondrial disorders. Current Opinion in Neurology, 1997, 10, 43-48.	3.6	12
309	Role of the Pharmacist in the Effective Management of Wearing-Off in Parkinson's Disease. Annals of Pharmacotherapy, 2007, 41, 1842-1849.	1.9	12
310	Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways. Free Radical Biology and Medicine, 2021, 175, 42-55.	2.9	12
311	Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group. British Journal of Hospital Medicine, 1998, 59, 469-80.	0.2	12
312	Mitochondrial myopathies BMJ: British Medical Journal, 1989, 298, 1127-1128.	2.3	11
313	HLA class II genotypes in Leber's hereditary optic neuropathy. Journal of the Neurological Sciences, 1994, 126, 193-196.	0.6	11
314	Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity. Neurology, 2000, 55, 1235-1235.	1.1	11
315	Progress in Parkinson's disease. European Journal of Neurology, 2007, 15, 1-1.	3.3	11
316	Movement disorders: advances in cause and treatment. Lancet Neurology, The, 2010, 9, 6-7.	10.2	11
317	Safinamide for the treatment of Parkinson's disease. Expert Opinion on Pharmacotherapy, 2017, 18, 937-943.	1.8	11
318	Mitochondrial function and neurotoxicity Editorial review. Current Opinion in Neurology, 1994, 7, 531-534.	3.6	10
319	Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Parkinsonism and Related Disorders, 1999, 5, 139-143.	2.2	10
320	Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats. Neurobiology of Disease, 2014, 64, 36-47.	4.4	10
321	The biochemical basis of interactions between Glucocerebrosidase and alphaâ€synuclein in <i>GBA</i> 1 mutation carriers. Journal of Neurochemistry, 2020, 154, 11-24.	3.9	10
322	Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S <i>GBA1</i> mutation model. Human Molecular Genetics, 2022, 31, 2396-2405.	2.9	10
323	Mitochondrial cytopathies. Current Opinion in Neurobiology, 1993, 3, 760-767.	4.2	9
324	Mitochondrial DNA in idiopathic cardiomyopathy. European Heart Journal, 1998, 19, 1725-1729.	2.2	9

#	Article	IF	CITATIONS
325	Rasagiline in neurodegeneration. Experimental Neurology, 2008, 212, 255-257.	4.1	9
326	Parkinsonism in patients with chronic hepatitis C treated with interferon-α2b: a report of two cases. European Journal of Gastroenterology and Hepatology, 2010, 22, 628-631.	1.6	9
327	LRRK2 as a therapeutic target in Parkinson's disease. European Journal of Neurology, 2011, 18, 545-546.	3.3	9
328	The Cytomegalovirus protein pUL37×1 targets mitochondria to mediate neuroprotection. Scientific Reports, 2016, 6, 31373.	3.3	9
329	Electron Transport Chain Defects in Alzheimer's Disease. Neurology, 1995, 45, 599-600.	1.1	8
330	Genetic counselling in mitochondrial diseases. Current Opinion in Neurology, 1997, 10, 408-412.	3.6	8
331	Fits and strokes. Lancet, The, 2001, 358, 120.	13.7	8
332	The PINK1—Parkin mitophagy signalling pathway is not functional in peripheral blood mononuclear cells. PLoS ONE, 2021, 16, e0259903.	2.5	8
333	VANCOMYCIN DOSE FOR PSEUDOMEMBRANOUS COLITIS. Lancet, The, 1980, 316, 204.	13.7	7
334	Platelet aggregation in myotonia. Journal of the Neurological Sciences, 1985, 71, 351-357.	0.6	7
335	HLA class I genotypes in Leber's hereditary optic neuropathy. Journal of the Neurological Sciences, 1996, 135, 173-175.	0.6	7
336	Mitochondria in the etiology of Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 479-491.	1.8	7
337	Glucocerebrosidase 1 and leucineâ€rich repeat kinase 2 in Parkinson disease and interplay between the two genes. Journal of Neurochemistry, 2021, 159, 826-839.	3.9	7
338	The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease. Neurodegenerative Disease Management, 2021, 11, 451-458.	2.2	7
339	Timing the initiation of treatment in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 79, 615-615.	1.9	6
340	Neurodegenerative diseases in the era of targeted therapeutics: how to handle a tangled issue. Molecular and Cellular Neurosciences, 2015, 66, 1-2.	2.2	6
341	Systemic PTEN-Akt1-mTOR pathway activity in patients with normal tension glaucoma and ocular hypertension: A case series. Mitochondrion, 2017, 36, 96-102.	3.4	6
342	Biofluid Biomarkers in Parkinson's Disease: Clarity Amid Controversy. Movement Disorders, 2020, 35, 1128-1133.	3.9	6

#	Article	IF	CITATIONS
343	Neurotoxicity and the mechanisms of cell death in Parkinson's disease. Advances in Neurology, 1996, 69, 161-5.	0.8	6
344	Dorsal root ganglion proteins in Friedreich's ataxia. Neuroscience Letters, 1993, 163, 182-184.	2.1	5
345	Inborn and induced defects of the mitochondrial respiratory chain. Biochemical Society Transactions, 1994, 22, 996-1001.	3.4	5
346	Future Strategies for Neuroprotection in Parkinson's Disease. Neurodegenerative Diseases, 2010, 7, 210-212.	1.4	5
347	Novel pathogenic mutations in the glucocerebrosidase locus. Molecular Genetics and Metabolism, 2012, 106, 495-497.	1.1	5
348	Glucosylceramidase degradation in fibroblasts carrying bi-allelic Parkin mutations. Molecular Genetics and Metabolism, 2013, 109, 402-403.	1.1	5
349	Functional assessment of glucocerebrosidase modulator efficacy in primary patient-derived macrophages is essential for drug development and patient stratification. Haematologica, 2020, 105, e206-e209.	3.5	5
350	Intronic Haplotypes in the <scp> <i>GBA</i> </scp> Gene Do Not Predict Age at Diagnosis of Parkinson's Disease. Movement Disorders, 2021, 36, 1456-1460.	3.9	5
351	MPTP and other Parkinson-inducing agents. Current Opinion in Neurology and Neurosurgery, 1992, 5, 396-400.	0.4	5
352	One-step immunoaffinity purification of complex I subunits from beef heart mitochondria. Protein Expression and Purification, 1992, 3, 223-227.	1.3	4
353	Congenital muscular dystrophy with severe retrocollis and mental retardation: a report of two siblings Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 279-281.	1.9	4
354	Cardiac bioenergetics in Friedreich's ataxia. Annals of Neurology, 2003, 54, 552-552.	5.3	4
355	Relapsing neuropathy in an 18-year-old woman. Lancet Neurology, The, 2007, 6, 192-198.	10.2	4
356	Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Human Molecular Genetics, 2013, 22, 1697-1697.	2.9	4
357	A pragmatic, personalised approach to treatment initiation in Parkinson's disease. Lancet Neurology, The, 2020, 19, 376-378.	10.2	4
358	Pathogenetic insights into young-onset Parkinson disease. Nature Reviews Neurology, 2020, 16, 245-246.	10.1	4
359	<scp><i>LRRK2</i></scp> Parkinsonism: Does the Response to Gut Bacteria Mitigate the Neurological Picture?. Movement Disorders, 2021, 36, 71-75.	3.9	4
360	Progress in Parkinson's disease. Neurology, 2003, 61, .	1.1	4

#	Article	IF	CITATIONS
361	Update of the human MitBASE database. Nucleic Acids Research, 1999, 27, 143-146.	14.5	3
362	Patterns of treatment for restless legs syndrome in primary care in the United Kingdom. Clinical Therapeutics, 2008, 30, 405-418.	2.5	3
363	What is Parkinson's Disease? From Pathophysiology to Symptoms. , 0, , 1-39.		3
364	New LRRK2 variants identified in Parkinson's disease. European Journal of Neurology, 2011, 18, 369-370.	3.3	3
365	Mitochondrial DNA in Parkinson's disease. Advances in Neurology, 1999, 80, 233-7.	0.8	3
366	Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents. International Journal of Oncology, 2005, 27, 337.	3.3	2
367	Optimizing treatment for Parkinson's disease. European Journal of Neurology, 2012, 19, 1483-1486.	3.3	2
368	Mitochondrial DNA and disease: What happens when things go wrong. Biochemist, 2005, 27, 24-27.	0.5	2
369	Advances in the Understanding of the Cause of Parkinson's Disease. Journal of the Royal Society of Medicine, 1994, 87, 373-375.	2.0	2
370	Pseudomonas osteitis causing cranial nerve palsies Journal of Neurology, Neurosurgery and Psychiatry, 1985, 48, 1306-1307.	1.9	1
371	Polypeptide and glycoprotein abnormalities in dorsal root ganglia of streptozotocin-diabetic rats. Journal of the Neurological Sciences, 1989, 94, 147-161.	0.6	1
372	Neurology Postgraduate Medical Journal, 1991, 67, 509-531.	1.8	1
373	Colloidal Gold Staining and Immunodetection in 2-D Protein Mapping. , 1992, 80, 255-260.		1
374	Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. Journal of Neurochemistry, 2005, 92, 215-215.	3.9	1
375	1.167 PRODEST – Depressive symptoms in Parkinson's disease: Pattern across scales. Parkinsonism and Related Disorders, 2007, 13, S51.	2.2	1
376	Advances in neurology 2011–12. European Journal of Neurology, 2012, 19, 1267-1275.	3.3	1
377	Neurology in evolution 2014–2015. European Journal of Neurology, 2015, 22, 1493-1502.	3.3	1
378	Glucocerebrosidase Gene Mutation and Preclinical Markers of Parkinson Disease—Reply. JAMA Neurology, 2015, 72, 724.	9.0	1

#	Article	IF	CITATIONS
379	Glycogen storage disease type XV: A case report. Neuromuscular Disorders, 2015, 25, S221.	0.6	1
380	Advances in neurological research and practice. European Journal of Neurology, 2016, 23, 1685-1693.	3.3	1
381	Advances and insights into neurological practice 2016â~'17. European Journal of Neurology, 2017, 24, 1425-1434.	3.3	1
382	Use of general practitioner computerised records to create a population based twin sample: pilot study based on Parkinson's disease. BMJ: British Medical Journal, 1997, 315, 1510-1511.	2.3	1
383	Neuroprotection in Parkinson's Disease. Advances in Behavioral Biology, 2002, , 373-378.	0.2	1
384	Unexpected findings of study of selegiline have not been treated with caution its authors advised. BMJ: British Medical Journal, 1997, 315, 370-370.	2.3	1
385	Colloidal Gold Staining and Immunodetection in 2D Protein Mapping. Methods in Molecular Biology, 1998, 80, 237-241.	0.9	1
386	The mitochondrial myopathies. Defects of the mitochondrial respiratory chain and oxidative phosphorylation system. Electroencephalography and Clinical Neurophysiology Supplement, 1987, 39, 103-14.	0.0	1
387	HOW DOES LIGNOCAINE PREVENT VENTRICULAR FIBRILLATION?. Lancet, The, 1981, 318, 1167-1168.	13.7	0
388	British neurology: a national focus Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1136-1136.	1.9	0
389	PRIMARY AND SECONDARY DEFICIENCIES OF THE MITOCHONDRIAL RESPIRATORY CHAIN. Neurologist, 1998, 4, 169-179.	0.7	0
390	Mitochondria: Aspects for neuroprotection. Drug Development Research, 1999, 46, 57-66.	2.9	0
391	Oxidative Stress and Huntingtonâ $\in$ Ms Disease. Oxidative Stress and Disease, 2003, , .	0.3	0
392	Measuring the Effects of Therapy in Parkinson Disease—Reply. JAMA - Journal of the American Medical Association, 2004, 291, 2430.	7.4	0
393	Disorders of the mitochondrial respiratory chain. , 2005, , 909-926.		0
394	2.421 A proteomics and behavioral analysis of the interaction of statins with mitochondrial proteins in a rat model of Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, S133.	2.2	0
395	2.IS.1. New treatment possibilities with oral Levodopa (Novartis Pharma AG/Orion Corporation). Parkinsonism and Related Disorders, 2007, 13, S144-S145.	2.2	0
396	3.IS.1. Continuous delivery of ropinirole: Improving the management of Parkinson's disease (GlaxoSmithKline). Parkinsonism and Related Disorders, 2007, 13, S190.	2.2	0

#	Article	IF	CITATIONS
397	MITOCHONDRIAL DNA AND DISEASE. CONTINUUM Lifelong Learning in Neurology, 2008, 14, 133-148.	0.8	0
398	Treatment of Parkinson's Disease. , 0, , 40-62.		0
399	Neurology in the <i>European Journal of Neurology</i> . European Journal of Neurology, 2010, 17, 1397-1406.	3.3	0
400	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. Neurodegenerative Disease Management, 2011, 1, 441-443.	2.2	0
401	Publishing changes and information delivery in the clinical neurosciences. European Journal of Neurology, 2011, 18, 1365-1372.	3.3	Ο
402	Role of Mitochondria in Parkinson's Disease and Huntington's Disease. Oxidative Stress and Disease, 2012, , 415-431.	0.3	0
403	Caveolinopathy presenting with muscle pain and rhabdomyolysis. Neuromuscular Disorders, 2015, 25, S297.	0.6	Ο
404	What would James Parkinson think? A virtual dialogue on factors influencing the development of Parkinson's disease. Movement Disorders, 2017, 32, 1499-1500.	3.9	0
405	Combined GCASE/ALPHA-synuclein pattern may identify specific prodomal PD patterns in GBA carriers: A cluster analysis study. Journal of the Neurological Sciences, 2021, 429, 119455.	0.6	0
406	Advances in the understanding of the cause of Parkinson's disease. Journal of the Royal Society of Medicine, 1994, 87, 373-5.	2.0	0
407	The use of toxins to elucidate neural function and disease. Current Opinion in Neurology and Neurosurgery, 1993, 6, 448-51.	0.4	0
408	Title is missing!. , 2020, 15, e0238075.		0
409	Title is missing!. , 2020, 15, e0238075.		Ο
410	Title is missing!. , 2020, 15, e0238075.		0
411	Title is missing!. , 2020, 15, e0238075.		Ο
412	Somatic copy number variant mutations in alpha-synuclein and genome-wide in brains of synucleinopathy cases. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A4.2-A4.	1.9	0